



CASE 33515P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

786957254 US

Express Mail Label Number

July 26, 2007

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

PATEL ET AL.

APPLICATION NO: 10/743,367

FILED: DECEMBER 22, 2003

FOR: EXTENDED RELEASE ANTIBIOTIC COMPOSITION

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 3, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

07/27/2007 RMEBRAHT 00000043 190134 10743367

02 FC:1806

180.00 DA

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8508

Date:

07/26/07

Respectfully submitted,

Joseph T. Majka
Attorney for Applicants
Reg. No. 30,570

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./



CASE 33515P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

PATEL ET AL.

APPLICATION NO: 10/743,367

FILED: DECEMBER 22, 2003

FOR: EXTENDED RELEASE ANTIBIOTIC COMPOSITION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8508
Date: 07/26/07



Joseph T. Majka
Attorney for Applicants
Reg. No. 30,570

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.

33515P1

APPLICATION NO.

10/743,367

APPLICANT

PATEL ET AL.

FILING DATE

DECEMBER 22, 2003

Group
1615

PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Dow Excipients, METHOCEL Products, www.dow.com
AS	Ethylcellulose, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, 1986, pages 113-115
AT	Methylcellulose, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, 1986, pages 181-183

EXAMINER

/Paul Ward/ (08/10/2010)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./